Relationship Between Weight, Efavirenz Exposure, and Virologic Suppression in HIV-Infected Patients on Rifampin-Based Tuberculosis Treatment in the AIDS Clinical Trials Group A5221 STRIDE Study

Background. Rifampin (RIF) upregulates CYP 450 isoenzymes, potentially lowering efavirenz (EFV) exposure. The US EFV package insert recommends an EFV dose increase for patients on RIF weighing ≥50 kg. We conducted a pharmacokinetic study to evaluate EFV trough concentrations (C(min)) and human immun...

Полное описание

Сохранить в:
Библиографические подробности
Главные авторы: Luetkemeyer, Anne F., Rosenkranz, Susan L., Lu, Darlene, Marzan, Florence, Ive, Prudence, Hogg, Evelyn, Swindells, Susan, Benson, Constance A., Grinsztejn, Beatriz, Sanne, Ian M., Havlir, Diane V., Aweeka, Francesca
Формат: Artigo
Язык:Inglês
Опубликовано: Oxford University Press 2013
Предметы:
HIV/AIDS
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC3719885/
https://ncbi.nlm.nih.gov/pubmed/23592830
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/cid/cit246
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы